Skip to content

Atrial Fibrillation Trial To Eliminate Risk-factors

Atrial Fibrillation Trial To Eliminate Risk-factors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05718336
Acronym
AFTTER
Enrollment
343
Registered
2023-02-08
Start date
2020-05-01
Completion date
2024-08-31
Last updated
2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial Fibrillation

Brief summary

The goal of this prospective-enrolling cohort study is to test and observe the effect of an integrated multi-discipline care program in patients with atrial fibrillation. The main questions it aims to answer are: 1. to understand the baseline characteristics and to explore the occult risk factors of the patients with AF; 2. to monitor the treatment efficacy of the patients undergoing integrated care and potentially concur the clinical obstacles that prevent the best care for patients with AF. Participants will be treated by an integrated multi-discipline team that led by an electro-physiologist.

Detailed description

Atrial fibrillation (AF) is a heart condition that potentially leads to heart failure and ischemic stroke. The prevalence of AF is increasing due to aging population and improved treatment in other cardiovascular field. This study is to execute integrated multi-discipline care in a tertiary hospital, and to observe the effect and the obstacle that the program might ensue.

Interventions

multi-discipline care program

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years old, who have been diagnosed with atrial fibrillation by a cardiologist with an electrocardiogram

Exclusion criteria

1. Unable to complete the initial assessment and cooperate with the tracker 2. Those who refuse to sign the subject's consent

Design outcomes

Primary

MeasureTime frameDescription
AF burden0~24 monthsThe duration in AF on 14-day ECG monitor (percent)

Secondary

MeasureTime frameDescription
MACE, major adverse cardiovascular event0~24 monthsischemic heart disease with acute coronary syndrome, stroke (either ischemic or hemorrhagic stroke), cardiovascular death, and all-cause death

Countries

Taiwan

Contacts

PRINCIPAL_INVESTIGATORChih-Chieh Yu, MD.PhD

National Taiwan University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026